| Matt Scott wins big for Dr. Mel Fund |
|
|
| Written by JBaileyAdmin | |
| Saturday, 14 April 2007 | |
|
Once again the poker playing skills of WTNH-TV meterologist Matt Scott have helped to grow the Dr. Mel Goldstein Multiple Myeloma Fund.
Matt finished in second place March 28, 2007, at the annual Foxwoods Poker Classic Charity Media Showdown. He collected a check for $7,000.
Over the years Matt has donated thousands of dollars in winnings to the fund, to which we say thank you, thank you, once again. And just because we know you'd be curious, this year's winner was reporter Jim Altman from WTIC-TV in Hartford. He collected $15,000 for his charity, The Fox 61 Family Fund. |
The event took place during the Foxwoods Poker Classic, an event on the World Poker Tour. | < Prev | Next > |
|---|
Multiple Myeloma News Update
-
Reader to Reader: Sept. 4
London Free Press
15, the London and District Multiple Myeloma Support Group held its second annual Dorchester Walk of Champions for myeloma research. ... -
Beacon NewsFlashes – September 3, 2010
The Myeloma Beacon
Revlimid is approved in the US for the treatment of multiple myeloma as well as a collection of blood disorders called myelodysplastic syndromes. ...
Celgene Officially Notified of ANDA Filing for REVLIMID(R)Trading Markets (press release)
Beacon NewsFlashes – September 3, 2010The MDS Beacon
all 32 news articles » -
TheMedGuruLisa Ray Talks On Struggle Against Cancer
Bollywood Non-Stop
The actress has taken multiple myeloma on 23 June 2009 and started her first cycle of treatment for cancer on 2 July 2009. Lisa Ray has announced on April ...
Lisa Ray - Fighting against CancerBreakingNewsOnline.
Lisa Ray talks about breast cancer!FitnHit.com (blog)
After cancer battle, Lisa Ray spreads hopeDaily News & Analysis
MSN India
all 21 news articles » -
GBI Research's report analyzes licensing agreement to shape global market
News-Medical.net
GBI Research's report, "Epigenetics Therapeutics to 2017 - High Market Potential for Epigenetics Drugs in Acute Myeloid Leukemia, Multiple Myeloma and ... -
A Look at Immunogen Beyond the T-DM1 Setback
Seeking Alpha (blog)
The second trial is a phase I in multiple myeloma that will probably be reported at ASH in December. I reviewed earlier results from this trial here. ...
and more » -
Guide To Nutrition In Multiple Myeloma – Part 2: Supplements
The Myeloma Beacon
This article is the second in a two-part series about nutrition for multiple myeloma patients. The first article provides an introduction to nutrition for ...
Pat's Place: A Patient's Reflections On The Progress Of Multiple Myeloma ResearchThe Myeloma Beacon
all 2 news articles » -
Bone morphogenetic protein-2 higher in patients with multiple myeloma
HemOncToday
Results from a recent study showed that bone morphogenetic protein-2 was a mediator for hepcidin-stimulatory capacity in multiple myeloma sera, ... -
NICE backs Thalidomide and Velcade for multiple myeloma
Pharma Times
Celgene's Thalidomide and Janssen-Cilag's Velcade have been recommended as options to treat patients with multiple myeloma on the National Health Service by ...